Search results
It Looks Like Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO May Expect Their Salary To Be Put...
Simply Wall St. via Yahoo Finance· 3 days agoKey Insights Intellia Therapeutics will host its Annual General Meeting on 12th of June CEO John...
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
Motley Fool via Yahoo Finance· 28 minutes agoIn fact, she added to positions in those companies over the past several days. I'm talking about...
These 2 Words Are Why Intellia Therapeutics Could Be a Smart Buy Right Now
Motley Fool via Yahoo Finance· 23 hours agoOn June 2, Intellia Therapeutics' (NASDAQ: NTLA) CEO John Leonard remarked on the biotech's progress...
Intellia Therapeutics Inc [NTLA] Insider Activity: An Update for Investors – Knox Daily
Knox Daily· 5 days agoIntellia Therapeutics Inc’s filing revealed that its EVP, General Counsel BASTA JAMES unloaded Company’s shares for reported $75778.0 on Mar 04 ’24. In ...
Intellia Up on Upbeat Long-Term Angioedema Study Data - Annovis Bio (NYSE:ANVS), ALX Oncology...
Benzinga· 5 days agoIntellia Therapeutics' NTLA shares gained 10% on Jun 3 after the company reported encouraging...
Is Intellia Therapeutics, Inc. (NASDAQ:NTLA) the Most Promising Gene Therapy Stock to Buy Now?
Insider Monkey via Yahoo Finance· 6 days agoWe recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we...
Why Intellia Therapeutics Shares Are Trading Higher Monday - Intellia Therapeutics (NASDAQ:NTLA)
Benzinga· 6 days agoIntellia Therapeutics, Inc. NTLA stock is moving higher Monday after the company announced long-term...
Cracking The Code: Understanding Analyst Reviews For Intellia Therapeutics - Intellia Therapeutics...
Benzinga· 5 days agoLoading... Loading... In the last three months, 4 analysts have published ratings on Intellia Therapeutics NTLA , offering a diverse range of perspectives ...
Intellia Therapeutics shares retain buy rating on strong study results By Investing.com
Investing.com· 6 days agoOn Monday, TD Cowen maintained a Buy rating on shares of Intellia Therapeutics (NASDAQ:NTLA), a...
Intellia’s CRISPR drug shows promise against hereditary angioedema in early-stage trial - Boston...
The Business Journals· 7 days agoOn Sunday, Intellia Therapeutics (Nasdaq: NTLA) said that its experimental gene-editing treatment...